VistaGen Therapeutics Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 34

Employees
  • Stock Symbol
  • VTGN

Stock Symbol
  • Investments
  • 3

  • Share Price
  • $0.27

  • (As of Thursday Closing)

VistaGen Therapeutics General Information

Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 343 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

VistaGen Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VistaGen Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.27 $0.25 $0.08 - $1.79 $51.3M 207M 6.53M -$0.32

VistaGen Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV (16,545) 175,536 205,791 24,772
Revenue (186) 1,109 1,090 0
EBITDA (63,784) (47,068) (17,456) (20,698)
Net Income (64,483) (47,762) (17,934) (20,774)
Total Assets 40,702 74,643 108,281 5,772
Total Debt 3,566 3,039 3,719 4,092
Public Fundamental Data provided by Morningstar, Inc. disclaimer

VistaGen Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.

Request a free trial

VistaGen Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and co
Biotechnology
South San Francisco, CA
34 As of 2022
000.00
000000000 000.00

000000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. U
0000 000000000
Coral Gables, FL
00 As of 0000
000.00
000000000 000.00

000000

lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000 000000000
Evanston, IL
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VistaGen Therapeutics Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relmada Therapeutics Formerly Angel backed Coral Gables, FL 00 000.00 000000000 000.00
0000000 Formerly VC-backed Evanston, IL 00 00000 00000000 00000
0000000000000 0000 Formerly VC-backed New York, NY 000 00000 000000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
0000000000 0000000 Formerly VC-backed San Diego, CA 0000 00000 00000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

VistaGen Therapeutics Patents

VistaGen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3178758-A1 Treatment of adjustment disorders Pending 18-May-2020
AU-2021277216-A1 Treatment of adjustment disorders Pending 18-May-2020 0000000000
AU-2020271853-A1 Genetic variants associated with response to treatment of neurological disorders Pending 09-Apr-2019 0000000000
CA-3136418-A1 Genetic variants associated with response to treatment of neurological disorders Pending 09-Apr-2019 0000000000
EP-3952856-A4 Genetic variants associated with response to treatment of neurological disorders Pending 09-Apr-2019 A61K31/198 0
To view VistaGen Therapeutics’s complete patent history, request access »

VistaGen Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Shawn Singh JD Chief Executive Officer & Board Member
Jerrold Dotson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Reid Adler JD Chief Legal Officer, Legal
Caren Scannell Director, Corporate Development and Communications
Ann Cunningham Board Member & Executive
You’re viewing 5 of 10 executive team members. Get the full list »

VistaGen Therapeutics Board Members (5)

Name Representing Role Since
000 0000000000 VistaGen Therapeutics Board Member & Executive 000 0000
000 0000 00 Self Chairman & Board Member 000 0000
000000 00000000000 VistaGen Therapeutics Board Of Director 000 0000
00000 00000 00 VistaGen Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

VistaGen Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VistaGen Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.

Request a free trial

VistaGen Therapeutics Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 21-Dec-2022 0000000000 Drug Discovery 00000 000
000000000 000 11-May-2011 0000000000 Distributors/Wholesale 00000 000
Artemis Neuroscience 19-Nov-2003 Merger/Acquisition Pharmaceuticals
To view VistaGen Therapeutics’s complete acquisitions history, request access »

VistaGen Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

34.38 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view VistaGen Therapeutics’s complete esg history, request access »